Posted: May 27, 2019
Mesothelioma is a rare tumor with limited treatment options. The upcoming IASLC 2019 Mesothelioma Meeting (July 10-12) in New York City—a first of its kind for this disease site—promises to provide the latest clinical trial and emerging therapy information in the field. Preclinical and early clinical trial data will be presented for experimental and approved agents, and early predictive biomarkers also will be discussed. This meeting is a unique resource for clinical investigators and clinical care providers alike from around the globe. ✦
“This meeting is unique, as it takes a different format than other meetings. This is rapid-fire learning, with debates on controversial concepts in genetic profiling and biomarker standards. The combination and pipeline immunotherapy agents section will definitely be a highlight at this meeting. Because we are only at the beginning of our understanding about mesothelioma immunogenicity, research strategies to augment and sustain the immune response against mesothelioma are critical to prolong survival. The meeting offers discussion about combination and pipeline immunotherapy agents that promises to be thought provoking.” –Dr. Anne S. Tsao, meeting co-chair
